KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.

Priya S Kishnani, Jordi Díaz-Manera, Sergey Illarioshkin, Ans T van der Ploeg, Paula R Clemens, John W Day, Antonio Toscano, Hani Kushlaf, Shafeeq Ladha, Shahram Attarian, Gerson Carvalho, Anna Kostera-Pruszczyk, Sevim Erdem-Özdamar, Ozlem Goker-Alpan, Tahseen Mozaffar, Volker Straub, Mark Roberts, Kristina An Haack, Olivier Huynh-Ba, Swathi Tammireddy, Magali Periquet, Nathan Thibault, Tianyue Zhou, Mazen M Dimachkie, Benedikt Schoser, COMET Investigator Group

J Neurol 272(9) 581

PMID40817977
PMCIDPMC12357813
DOI10.1007/s00415-025-13266-y
发表日期2025-08-16
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。
摘要

摘要

BACKGROUND AND OBJECTIVES: In the COMET trial, avalglucosidase alfa treatment for late-onset Pompe disease was safe, tolerable and associated with stabilization or improvement in disease parameters through 97 weeks. We report outcomes in the trial extension through 145 weeks of treatment. METHODS: In this phase 3, double-blind, randomized trial, participants with previously untreated late-onset Pompe disease were randomly assigned to receive 20 mg/kg avalglucosidase alfa or alglucosidase alfa every other week for 49 weeks; thereafter, all patients received 20 mg/kg avalglucosidase alfa every other week. For this analysis, efficacy was assessed at 145 weeks and safety to last follow-up (data cutoff: March 11, 2022). RESULTS: Of 100 participants in the double-blind treatment period, 95 entered the open-label extension, and 88 completed ≥ 145 weeks of treatment. At study start, the mean upright FVC percent predicted was similar between treatment arms, and 6MWT distance was greater in the avalglucosidase alfa arm. From baseline to week 145, the LS mean (SE) FVC percent predicted increased by 1.38 (1.22) in the avalglucosidase alfa arm and 1.25 (1.34) in the switch arm. The LS mean (SE) 6MWT distance walked increased by 20.65 (9.60) m and 0.29 (10.42) m, respectively. Potentially treatment-related adverse events were reported in 27 patients (53%) in the avalglucosidase alfa arm and 25 patients (57%) in the switch arm. Anti-drug antibodies declined over time in both arms. CONCLUSIONS: In this randomized clinical trial extension, positive clinical outcomes were maintained for patients taking avalglucosidase alfa for up to 145 weeks with no new safety concerns. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02782741, https://clinicaltrials.gov/ct2/show/NCT02782741 . Registration date: 2016-05-23; Date of first patient enrolled: 2016-11-02.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Least squares (LS) mean change in respiratory function parameters from baseline to week 145. A Upright FVC percent predicted. B Upright MIP percent predicted. C Upright MEP percent predicted. FVC: forced vital capacity; MEP: maximal expiratory pressure; MIP; maximal inspiratory pressure; SE, standard error. *1 participant’s FVC percent predicted value at week 97 was excluded due to a physiologically implausible change between weeks 73 & 97 and 97 & 121. † 4 participants (2 in each group) were excluded from the MIP and MEP percent predicted analyses due to implausible values at baseline
非 KM Figure
Fig. 2Fig. 2 Least squares (LS) mean change in functional and motor parameters from baseline to week 145. A Six-minute walk test (6MWT). B Lower extremity hand-held dynamometry (HHD). C Quick Motor Function Test (QMFT). D Short-form 12-item (SF-12) physical component summary (PCS). SE: standard error. Note: Two participants in the avalglucosidase alfa arm had unexplained decreases in HHD (lower extremity) composite scores from Week 61 to 73, which contributed substantially to the group LS mean decrease during that time interval. Scores for both participants stabilized following Week 73. No participant- or treatment-related factors were identified as reasons for this decrease
非 KM Figure
Fig. 3Fig. 3 Mean percent change in biomarkers from baseline to week 145. A Urinary hexose tetrasaccharide (HEX 4 ). B Serum creatine kinase (CK). SD: standard deviation
非 KM Figure
Fig. 4Fig. 4 Anti-avalglucosidase alfa antibody titers at weeks 49, 97 and 145. A Participants in the avalglucosidase alfa arm. B Participants who switched from alglucosidase alfa to avalglucosidase alfa at week 49. Percentages are based on the number of participants at week 49. At some timepoints, the total number of participants across titer categories is less than 100% due to the number of participants with available data and participant discontinuations
非 KM Figure